FTY720 (Fingolimod) is a known sphingosine-1-phosphate (S1P) receptor agonist that
exerts strong anti-inflammatory effects and was approved as the first oral drug for the …

Finding novel and effective drugs for the treatment of ischemic stroke is warranted because
there is not a definitive treatment for this prevalent disease. Due to the relevance between …

Abstract Background FTY720 (fingolimod, Gilenya™), a structural analog of sphingosine-1-
phosphate (S1P), is the first oral drug approved for treatment the relapsing-remitting form of …

Central nervous system (CNS) injuries, such as traumatic brain injury (TBI), subarachnoid
hemorrhage (SAH) and intracerebral hemorrhage (ICH), are important causes of disability …

Fingolimod (FTY720) is an orally bio-available immunomodulatory drug currently approved
by the FDA for the treatment of multiple sclerosis. Currently, there is a significant interest in …

FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous
lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation …

Background and Purpose: FTY720 (fingolimod) is a known sphingosine-1-phosphate (S1P)
receptor agonist, which has been used in clinical trials for treating multiple sclerosis, renal …

Background and Purpose—Lymphocytes are important players in the pathophysiology of
acute ischemic stroke. The interaction of lymphocytes with endothelial cells and platelets …

FTY720 (fingolimod; Gilenya®), a sphingosine 1-phosphate (S1P) receptor modulator, is the
first oral disease-modifying therapy to be approved for the treatment of relapsing–remitting …

Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The
current therapies available for MS work by an immunomodulatory action, preventing T-cell …